Oxaliplatin

Generic Name
Oxaliplatin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C8H14N2O4Pt
CAS Number
61825-94-3
Unique Ingredient Identifier
04ZR38536J
Background

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...

Indication

Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.

Associated Conditions
Advanced Colorectal Cancer, Stage III Colon Cancer
Associated Therapies
-
Clinical Trials
Related News

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

First Posted Date
2023-11-08
Last Posted Date
2024-10-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
25
Registration Number
NCT06123338
Locations
🇺🇸

Johns Hopkins University (Data Collection Only), Baltimore, Maryland, United States

🇺🇸

Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts, United States

🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 6 locations

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

First Posted Date
2023-10-31
Last Posted Date
2024-05-03
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
36
Registration Number
NCT06109467
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

First Posted Date
2023-10-23
Last Posted Date
2024-12-03
Lead Sponsor
Australasian Gastro-Intestinal Trials Group
Target Recruit Count
20
Registration Number
NCT06094140
Locations
🇦🇺

GenesisCare North Shore, Sydney, New South Wales, Australia

🇦🇺

Wollongong Hospital, Wollongong, New South Wales, Australia

🇦🇺

Warringal Private Hospital, Melbourne, Victoria, Australia

Preoperative Hypofractionated Radiotherapy with FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

First Posted Date
2023-10-12
Last Posted Date
2024-10-02
Lead Sponsor
Mayo Clinic
Target Recruit Count
99
Registration Number
NCT06078709
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

First Posted Date
2023-09-18
Last Posted Date
2023-09-18
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
115
Registration Number
NCT06041035
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

First Posted Date
2023-09-08
Last Posted Date
2023-09-08
Lead Sponsor
Ukrainian Society of Clinical Oncology
Target Recruit Count
758
Registration Number
NCT06028737
Locations
🇺🇦

National Cancer Institute, Kyiv, Ukraine

Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer

First Posted Date
2023-08-30
Last Posted Date
2023-10-11
Lead Sponsor
Yong Zhang,MD
Target Recruit Count
48
Registration Number
NCT06017583
Locations
🇨🇳

First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

First Posted Date
2023-08-25
Last Posted Date
2024-05-03
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
42
Registration Number
NCT06011772
Locations
🇺🇸

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.

First Posted Date
2023-08-18
Last Posted Date
2023-08-18
Lead Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Target Recruit Count
60
Registration Number
NCT05997524
Locations
🇧🇩

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

First Posted Date
2023-08-03
Last Posted Date
2023-08-03
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
20
Registration Number
NCT05974059
Locations
🇨🇳

Xuewei Ding, Tianjin, Tianjin, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy